Payment overview · 2025
General Payments
We did not find matching Open Payments records for this doctor in the selected program year.
Healthcare provider profile · identity verified
Ajay Kumar, MD
Endocrinology · GREENSBORO, NC · NPI 1962426817
Verified facts
What the public records show
We did not find matching Open Payments records for this doctor in 2025.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Analysis 1 · Payment-linked products
Products named in Open Payments records
No payment-linked product analysis is available because no matching General Payment records were found for the selected year.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
There is no payer-company set available for this comparison.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 370 | 111 |
| Ozempic | Semaglutide | 291 | 59 |
| Jardiance | Empagliflozin | 284 | 68 |
| Metformin Hcl Er | Metformin Hcl | 240 | 76 |
| Mounjaro | Tirzepatide | 190 | 43 |
| Farxiga | Dapagliflozin Propanediol | 177 | 42 |
| Glimepiride | Glimepiride | 154 | 45 |
| Metformin Hcl | Metformin Hcl | 132 | 45 |
| Tresiba Flextouch U-100 | Insulin Degludec | 128 | 39 |
| Novolog Flexpen | Insulin Aspart | 122 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 34 |
| Trulicity | Dulaglutide | 92 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 87 | 33 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 86 | 27 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 84 | 20 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 82 | 19 |
| Novolog | Insulin Aspart | 81 | 19 |
| Humalog | Insulin Lispro | 79 | 17 |
| Atorvastatin Calcium | Atorvastatin Calcium | 78 | 26 |
| Tresiba Flextouch U-200 | Insulin Degludec | 77 | 20 |
| Gabapentin | Gabapentin | 74 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 71 | 26 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 68 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 19 |
| Rybelsus | Semaglutide | 63 | 14 |
| Synthroid | Levothyroxine Sodium | 62 | 20 |
| Repaglinide | Repaglinide | 57 | 25 |
| Invokana | Canagliflozin | 54 | 13 |
| Ezetimibe | Ezetimibe | 51 | 16 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 49 | 11 |
| Losartan Potassium | Losartan Potassium | 44 | 12 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 12 |
| Amlodipine Besylate | Amlodipine Besylate | 39 | 15 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 36 | suppressed |
| Testosterone | Testosterone | 36 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | 15 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | 12 |
| Simvastatin | Simvastatin | 29 | 11 |
| Glipizide Er | Glipizide | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Lyumjev | Insulin Lispro-Aabc | 23 | suppressed |
| Lisinopril | Lisinopril | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Insulin Lispro | Insulin Lispro | 20 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 20 | suppressed |
| V-Go 20 | Sub-Q Insulin Device, 20 Unit | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Kerendia | Finerenone | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Novolin R | Insulin Regular, Human | 15 | suppressed |
| Acarbose | Acarbose | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Isradipine | Isradipine | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Jatenzo | Testosterone Undecanoate | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Euthyrox | Levothyroxine Sodium | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | — | — | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error